Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Ein weiblicher Säugling mit papulovesikulären Läsionen.

Veronese F, Zavattaro E, Monzani A, Zaffaroni M, Landucci G, De Miglio L, Nugnes M, Savoia P.

J Dtsch Dermatol Ges. 2018 Nov;16(11):1383-1386. doi: 10.1111/ddg.13643_g. No abstract available.

PMID:
30395391
2.

A female newborn with papulovesicular lesions.

Veronese F, Zavattaro E, Monzani A, Zaffaroni M, Landucci G, De Miglio L, Nugnes M, Savoia P.

J Dtsch Dermatol Ges. 2018 Nov;16(11):1383-1386. doi: 10.1111/ddg.13643. Epub 2018 Aug 29. No abstract available.

PMID:
30157313
3.

Detecting Recovery Problems Just in Time: Application of Automated Linguistic Analysis and Supervised Machine Learning to an Online Substance Abuse Forum.

Kornfield R, Sarma PK, Shah DV, McTavish F, Landucci G, Pe-Romashko K, Gustafson DH.

J Med Internet Res. 2018 Jun 12;20(6):e10136. doi: 10.2196/10136.

4.

Rapid response to cyclosporine in a rare case of pityriasis rubra pilaris with autoantibodies and systemic symptoms.

Gironi LC, Tiberio R, Dagna L, Landucci G, Giacalone A, Boldorini RL, Colombo E, Savoia P.

G Ital Dermatol Venereol. 2018 Feb 7. doi: 10.23736/S0392-0488.18.05906-0. [Epub ahead of print] No abstract available.

PMID:
29417801
5.

DAMS: A Model to Assess Domino Effects by Using Agent-Based Modeling and Simulation.

Zhang L, Landucci G, Reniers G, Khakzad N, Zhou J.

Risk Anal. 2018 Aug;38(8):1585-1600. doi: 10.1111/risa.12955. Epub 2017 Dec 19.

PMID:
29266430
6.

SurvivorCHESS to increase physical activity in colon cancer survivors: can we get them moving?

Mayer DK, Landucci G, Awoyinka L, Atwood AK, Carmack CL, Demark-Wahnefried W, McTavish F, Gustafson DH.

J Cancer Surviv. 2018 Feb;12(1):82-94. doi: 10.1007/s11764-017-0647-7. Epub 2017 Oct 9.

PMID:
28994035
7.

The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial.

Gustafson DH Sr, Landucci G, McTavish F, Kornfield R, Johnson RA, Mares ML, Westergaard RP, Quanbeck A, Alagoz E, Pe-Romashko K, Thomas C, Shah D.

Trials. 2016 Dec 12;17(1):592.

8.

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.

Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME.

J Immunol. 2016 Dec 15;197(12):4603-4612. Epub 2016 Nov 9.

9.

Application of Graph Theory to Cost-Effective Fire Protection of Chemical Plants During Domino Effects.

Khakzad N, Landucci G, Reniers G.

Risk Anal. 2017 Sep;37(9):1652-1667. doi: 10.1111/risa.12712. Epub 2016 Nov 10.

PMID:
27862134
10.

Using the NIATx Model to Implement User-Centered Design of Technology for Older Adults.

Gustafson DH Jr, Maus A, Judkins J, Dinauer S, Isham A, Johnson R, Landucci G, Atwood AK.

JMIR Hum Factors. 2016 Jan 14;3(1):e2. doi: 10.2196/humanfactors.4853.

11.

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens.

Asbach B, Kliche A, Köstler J, Perdiguero B, Esteban M, Jacobs BL, Montefiori DC, LaBranche CC, Yates NL, Tomaras GD, Ferrari G, Foulds KE, Roederer M, Landucci G, Forthal DN, Seaman MS, Hawkins N, Self SG, Sato A, Gottardo R, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo AD, Weiss DE, Francis J, Galmin L, Ding S, Heeney JL, Pantaleo G, Wagner R.

J Virol. 2016 Mar 28;90(8):4133-4149. doi: 10.1128/JVI.03135-15. Print 2016 Apr.

12.

Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations.

Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE Jr.

Mol Immunol. 2016 Feb;70:94-103. doi: 10.1016/j.molimm.2015.12.002. Epub 2015 Dec 31.

13.

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.

Santra S, Tomaras GD, Warrier R, Nicely NI, Liao HX, Pollara J, Liu P, Alam SM, Zhang R, Cocklin SL, Shen X, Duffy R, Xia SM, Schutte RJ, Pemble Iv CW, Dennison SM, Li H, Chao A, Vidnovic K, Evans A, Klein K, Kumar A, Robinson J, Landucci G, Forthal DN, Montefiori DC, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, Michael NL, Kim JH, Soderberg KA, Giorgi EE, Blair L, Korber BT, Moog C, Shattock RJ, Letvin NL, Schmitz JE, Moody MA, Gao F, Ferrari G, Shaw GM, Haynes BF.

PLoS Pathog. 2015 Aug 3;11(8):e1005042. doi: 10.1371/journal.ppat.1005042. eCollection 2015 Aug.

14.

Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein.

Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE Jr.

PLoS One. 2015 Jul 30;10(7):e0133509. doi: 10.1371/journal.pone.0133509. eCollection 2015.

15.

Assessment of fragment projection hazard: probability distributions for the initial direction of fragments.

Tugnoli A, Gubinelli G, Landucci G, Cozzani V.

J Hazard Mater. 2014 Aug 30;279:418-27. doi: 10.1016/j.jhazmat.2014.07.034. Epub 2014 Jul 21.

PMID:
25106043
16.

Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits.

Venditto VJ, Wieczorek L, Molnar S, Teque F, Landucci G, Watson DS, Forthal D, Polonis VR, Levy JA, Szoka FC Jr.

Clin Vaccine Immunol. 2014 Aug;21(8):1086-93. doi: 10.1128/CVI.00320-14. Epub 2014 May 28.

17.

Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge.

Gupta S, Pegu P, Venzon DJ, Gach JS, Ma ZM, Landucci G, Miller CJ, Franchini G, Forthal DN.

J Infect Dis. 2015 Jan 1;211(1):45-52. doi: 10.1093/infdis/jiu300. Epub 2014 May 21.

18.

HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.

Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, Forthal DN, Katlama C, Jung BH, Murphy RL.

PLoS One. 2014 Jan 15;9(1):e85371. doi: 10.1371/journal.pone.0085371. eCollection 2014.

19.

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.

Sholukh AM, Byrareddy SN, Shanmuganathan V, Hemashettar G, Lakhashe SK, Rasmussen RA, Watkins JD, Vyas HK, Thorat S, Brandstoetter T, Mukhtar MM, Yoon JK, Novembre FJ, Villinger F, Landucci G, Forthal DN, Ratcliffe S, Tuero I, Robert-Guroff M, Polonis VR, Bilska M, Montefiori DC, Johnson WE, Ertl HC, Ruprecht RM.

Retrovirology. 2014 Jan 20;11:8. doi: 10.1186/1742-4690-11-8.

20.

The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells.

Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN.

PLoS Pathog. 2013;9(11):e1003776. doi: 10.1371/journal.ppat.1003776. Epub 2013 Nov 21. Erratum in: PLoS Pathog. 2013 Nov;9(11). doi:10.1371/annotation/31430955-703b-484a-96eb-e180f917d683.

21.

Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.

Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, Sutton WF, Guo B, Reed JS, Leon EJ, Engelmann F, Zheng B, Legasse A, Park B, Dickerson M, Lewis AD, Colgin LM, Axthelm M, Messaoudi I, Sacha JB, Burton DR, Forthal DN, Hessell AJ, Haigwood NL.

J Virol. 2013 Oct;87(19):10447-59. doi: 10.1128/JVI.00049-13. Epub 2013 Jul 24.

22.

Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems.

Rosenberg Y, Sack M, Montefiori D, Forthal D, Mao L, Hernandez-Abanto S, Urban L, Landucci G, Fischer R, Jiang X.

PLoS One. 2013;8(3):e58724. doi: 10.1371/journal.pone.0058724. Epub 2013 Mar 22.

23.

Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection.

Forthal DN, Landucci G, Chohan B, Richardson BA, McClelland RS, Jaoko W, Blish C, Overbaugh J.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):31-3. doi: 10.1097/QAI.0b013e3182874d41.

24.

Association of Fcγ receptor IIIa genotype with the rate of HIV infection after gp120 vaccination.

Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB.

Blood. 2012 Oct 4;120(14):2836-42. doi: 10.1182/blood-2012-05-431361. Epub 2012 Aug 22.

25.

In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds.

Forthal DN, Phan TB, Slepenkin AV, Landucci G, Chu H, Elofsson M, Peterson E.

Int J Antimicrob Agents. 2012 Oct;40(4):354-60. doi: 10.1016/j.ijantimicag.2012.05.023. Epub 2012 Jul 20.

26.

Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.

Van Rompay KK, Trott KA, Jayashankar K, Geng Y, LaBranche CC, Johnson JA, Landucci G, Lipscomb J, Tarara RP, Canfield DR, Heneine W, Forthal DN, Montefiori D, Abel K.

Retrovirology. 2012 Jul 17;9:57. doi: 10.1186/1742-4690-9-57.

27.

A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR.

J Virol. 2012 Jun;86(11):6189-96. doi: 10.1128/JVI.00491-12. Epub 2012 Mar 28.

28.

Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

McBurney SP, Landucci G, Forthal DN, Ross TM.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1063-72. doi: 10.1089/AID.2011.0351. Epub 2012 Mar 21.

29.

Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques.

Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G.

Vaccine. 2011 Dec 9;30(1):78-94. doi: 10.1016/j.vaccine.2011.10.040. Epub 2011 Oct 27.

30.

IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation.

Forthal DN, Landucci G, Ding H, Kappes JC, Wang A, Thung I, Phan T.

AIDS. 2011 Nov 13;25(17):2099-104. doi: 10.1097/QAD.0b013e32834b64bd.

PMID:
21832933
31.

Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12.

Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H.

J Immunol. 2010 Dec 1;185(11):6876-82. doi: 10.4049/jimmunol.1002600. Epub 2010 Nov 1.

32.

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL.

Nat Med. 2010 Oct;16(10):1117-9. doi: 10.1038/nm.2233. Epub 2010 Oct 3.

33.

Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines.

Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF.

J Exp Med. 2010 Apr 12;207(4):763-76. doi: 10.1084/jem.20091281. Epub 2010 Apr 5.

34.

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR.

J Virol. 2010 Feb;84(3):1302-13. doi: 10.1128/JVI.01272-09. Epub 2009 Nov 11.

35.

The assessment of the damage probability of storage tanks in domino events triggered by fire.

Landucci G, Gubinelli G, Antonioni G, Cozzani V.

Accid Anal Prev. 2009 Nov;41(6):1206-15. doi: 10.1016/j.aap.2008.05.006. Epub 2008 Jun 12.

PMID:
19819369
36.

Modeling the performance of coated LPG tanks engulfed in fires.

Landucci G, Molag M, Cozzani V.

J Hazard Mater. 2009 Dec 15;172(1):447-56. doi: 10.1016/j.jhazmat.2009.07.029. Epub 2009 Jul 15.

PMID:
19656620
37.

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys.

Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal DN, Self SG, Carville A, Mansfield K, Goudsmit J.

J Virol. 2009 Sep;83(18):9584-90. doi: 10.1128/JVI.00821-09. Epub 2009 Jun 24.

38.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

39.

Antineoplastic activity of idazoxan hydrochloride.

Eilon GF, Weisenthal L, Stupecky M, Landucci G, Slater LM.

Cancer Chemother Pharmacol. 2009 Nov;64(6):1157-63. doi: 10.1007/s00280-009-0978-9. Epub 2009 Mar 24.

40.

Risk reduction in road and rail LPG transportation by passive fire protection.

Paltrinieri N, Landucci G, Molag M, Bonvicini S, Spadoni G, Cozzani V.

J Hazard Mater. 2009 Aug 15;167(1-3):332-44. doi: 10.1016/j.jhazmat.2008.12.122. Epub 2009 Jan 10.

PMID:
19188020
41.

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH.

Nature. 2009 Jan 1;457(7225):87-91. doi: 10.1038/nature07469. Epub 2008 Nov 9.

42.

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF.

J Virol. 2008 Dec;82(24):12449-63. doi: 10.1128/JVI.01708-08. Epub 2008 Oct 8.

44.

Experimental and analytical investigation of thermal coating effectiveness for 3m(3) LPG tanks engulfed by fire.

Landucci G, Molag M, Reinders J, Cozzani V.

J Hazard Mater. 2009 Jan 30;161(2-3):1182-92. doi: 10.1016/j.jhazmat.2008.04.097. Epub 2008 May 1.

PMID:
18541370
45.

Inherent safety key performance indicators for hydrogen storage systems.

Landucci G, Tugnoli A, Cozzani V.

J Hazard Mater. 2008 Nov 30;159(2-3):554-66. doi: 10.1016/j.jhazmat.2008.02.080. Epub 2008 Feb 29.

PMID:
18395975
46.

FcgammaRIIa genotype predicts progression of HIV infection.

Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B.

J Immunol. 2007 Dec 1;179(11):7916-23.

47.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
49.

Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge.

Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M.

J Immunol. 2006 Sep 15;177(6):4028-36.

50.

Supplemental Content

Loading ...
Support Center